IDH1 and acute myeloid leukemia: Hypomethylating agents (HMAs) such as azacitidine are de facto standard-of-care therapies for elderly AML unfit for induction therapy, and a clinical trial evaluating azacitidine in combination with enasidenib or ivosidenib in IDH-mutant AML is ongoing (NCT02677922).